Global Asthma Treatment Market By Treatment (Long-term Control Medications, Quick Relief Medications), By Route of Administration (Injectable, Oral, Inhaled), By Distribution Channel (Hospitals, Pharmacies & Drug Stores, Online Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Asthma Treatment Market size is expected to be worth around USD 38.3 Billion by 2033, from USD 26.1 Billion in 2023, growing at a CAGR of 3.9% during the forecast period from 2024 to 2033.

Asthma is a chronic respiratory condition characterized by inflammation, and narrowing of airways. The market for asthma treatment refers to the use of pharmaceuticals and device for managing and treating asthma. Asthma can be a minor annoyance for some people and can be a major tissue in others disrupting daily activities, resulting in life-threatening asthma exacerbation. Occupational asthma can be caused by irritants in the workplace such as gases, dust or chemical fumes. Allergy induced asthma can be as a result of airborne allergens such as pollen, cockroach waste, mold spores, and skin and dried saliva shed by pets.

• According to World Health Organization report on ‘The Global Impact of Respiratory Disease’, approximately 334 million individuals suffer from asthma.

The market further comprises a wide range of nebulizers, medications, inhalers and other devices aimed at relieving inflammation and thereby preventing asthma attacks. The market growth for asthma treatment is escalated by high level of strategic initiatives including collaborations and partnerships among the major industry players. Furthermore, rise in pervasiveness of asthma, rise in adoption of combination therapy, and surge in focus on development of digital/smart inhalers contribute towards market growth.

• A partnership was held between AstraZeneca and Avillion Company to develop ‘PT027’, an asthma rescue inhaler.
• According to World Health Organization, an approximate of 263 people were affected by asthma leading to death of 456,021 people across the globe.

Key Takeaways

• Based on type of treatment, asthma treatment market is majorly led by long term control medication market, capturing a valuable market share of 65.4% in the year 2023.
• Based on route of administration, a notable market shares of 53.8% is withheld by inhalation segment dominating the global market.
• Based on distribution channel, hospital pharmacies segment hold dominating position and holds 59.4% market share.
• Escalating pervasiveness of respiratory illnesses including asthma coupled with rapid product approvals boosts the market in recent years.
• North America is accounted to hold a large market revenue share of 51.2%, dominating the global asthma treatment market in the year 2023.

Treatment Analysis

Long-term control medication segment dominates the market

Based on treatment, the asthma treatment market is fragmented into Long-term control medication and quick relief medications. Amongst these, long-term control medication segment dominates the market by capturing a valuable market share of 65.4% in the year 2023.

Asthma being a chronic disease require long term medications for the control and management of asthma symptoms. To exemplify some of the key medications of the segment include Qvar, Symbicort, and Advair playing an instrumental role dominating the market in recent years. Combination corticosteroids, anticholinergics, immunomodulators and leukotriene modifiers are some of the key drug classes of long term control medication segment.

Quick relief medication segment on the other hand, is the another significant segment occupying the remaining portion of the market. The medications under this segment such as albuterol sulphate assist the patients in providing prompt relief from asthma symptoms by relaxing airway muscles.

Route of Administration Analysis

A market shares of 53.8% is captured by inhalation segment

Based on route of administration, the market is bifurcated into injectable, oral and inhalation segment. Commanding an impressive market share of 53.8%, inhalation segment dominates the asthma treatment market. The segment being predominant is majorly due to large number of products for treatment of asthma are administered in this form, such as Pulmicort and Qvar is given in inhalation form.

Injectable segment following closely to the inhalation segment, is projected to grow faster during the forecast period. This significance owes to a number of immune-modulators which is a key drug class used majorly for relieving severe symptoms of asthma.

Distribution Channel Analysis

Hospital pharmacies build trust among patients

Based on distribution channel, the market for asthma treatment is fragmented into hospital pharmacies, retail pharmacies and drug stores and online pharmacies. A commendable market shares of 59.4% is grabbed by hospital pharmacies segment, acting as a major market leader in the year 2023.

The dominance of the segment is highly ascribed to the therapeutics used in asthma treatment are often prescribed only in hospital settings by trained medical professionals. Prescription by trained healthcare professionals allow the patients to properly adhere to the treatment guidelines and also accurate and safe administration of critical therapeutics, especially administration done through subcutaneous injections. Thus, these factors ensure effective control of asthma symptoms.

A second largest market share is commanded by retail pharmacies and drug stores segment owing to refilling of asthma prescriptions such as inhaled corticosteroids easily carry out at these locations. Moreover, by virtue of ease and convenience given to patients with respect to acquisition of critical asthma medications, online pharmacies are estimated to grow at the highest CAGR during the forecast period.

Key Market segments

Treatment

• Long-term control medication
• Quick relief medication

Route of Administration Analysis

• Injectable
• Oral
• Inhalation

Distribution Channel

• Hospital pharmacies
• Retail pharmacies and drug stores
• Online pharmacies

Market Drivers

Prevalence of respiratory diseases

Asthma treatment market experiences a robust thrive owing to increasing prevalence of chronic respiratory diseases including asthma across the globe. Being a most common chronic disease worldwide, it necessitates the need for advanced therapeutics for treating symptoms of asthma. Treatment drugs are immediately required by the patients dealing with severe form of asthma, presenting a debilitating disease. Thus, the patients undergoing asthma treatment demands better quality of life, which further drives the market growth.

• Approximately 8.3% of children in United States had asthma in 2016, according to American Academy of Allergy, Asthma, and Immunology (AAAAI).

Rapid Product Approvals

The increasing approvals from regulatory authorities such as Food and Drug administration (FDA) has led to expediting launch of products of significant capability from prominent companies into the market. In addition, to avoid shortages of asthma medications, there is ongoing drug formulations and new launch of effective treatment products.

• In April 2020, Cipla’s key generic asthma treatment drug was approved by Food and Drug Administration (US).

Market Restraints

Escalated costs of Asthma medications

Certain restraining factors hampers the adoption of asthma medication despite asthma prevalence is on rise in both developing and developed countries. High cost of asthma medications, particularly asthma inhalers is one of the root cause hampering the growth of the market in recent years.

Such expensive medications may limit the adoption of asthma treatments especially in low and middle income countries, where a lot of people are going through asthmatic symptoms. A financial burden is created on patients without adequate insurance coverage. The reason behind high cost of medications is by virtue of development and manufacturing process of medications coupled with added cost due to research and development, clinical trials, and approvals by regulatory authorities.

• The process of Advair, a critical asthma drug has risen from the USD 316 in 2013 to the USD 496 in 2018, documenting an increase of 56.0%.

Opportunities

Innovative medications open up new growth pathways

The upgradations brought into asthma medications has fueled by asthma treatment market providing lucrative opportunities for major market players. One of the recent example of upgraded asthma treatment includes the use of biologics. A biologic is a drug derived from cells of living organisms such as bacteria or mice tailored to target particular molecules in humans.

Biologics attempt to disrupt the process of antibodies, inflammatory chemicals and cell receptors which are main targets for asthma leading to inflammation. Biologics are especially prescribed to those patients who still continue to witness asthmatic symptoms even after consuming normal daily controller drug.

Five biologics for asthma treatment are currently approved which include omalizumab, reslizumab, dupilumab, benralizumab and mepolizumab. Thus, the need for these biologics creates noteworthy opportunities for major market players involved in manufacturing of such medications, thereby resulting in economic growth of the market.

Latest Trends

Long-Acting Muscarinic Antagonists (LAMA’s)

These are maintenance or controller medicines that are taken as prescribed to limit inflammation in the airways, thereby reducing asthmatic symptoms.

Single Maintenance and Reliever Therapy (SMART)

The therapy is given to those patients with moderate to severe persistent asthma. The approach utilizes single inhaler containing inhaled corticosteroid coupled with inhaled long-acting beta2-agonists as the daily controller. Recently, two types of combination inhalers mometasone furoate and Budesonide are accessible for treating asthma.

Allergy testing and Shots

When allergens increase asthma symptoms allergy testing is used to control asthma. Upon identification of allergens causing asthma patient is asked to avoid or reduce exposure to those particular allergens or patient may be advised to receive allergy shots (immunotherapy) so as to scale the tolerance towards the allergens.

Impact of Macroeconomic factors

Globalization in the form of international trade and supply chain dynamics highly influences the availability and pricing of asthma medications. The expense of asthma treatments in diverse market is affected by the changes occurring in trade policies, currency exchange rates and tariffs. In addition to these, the severity of asthma coupled with its prevalence is also influenced by environmental factors such as climate change, allergen exposure, and air pollution.

The hike in these concerns demands for advanced asthma treatments, especially in high pollution level containing regions. And lastly, growth in economy impacts the overall purchasing power of patients combined with healthcare spending capacity. Higher the economic growth, more is the inclination towards medical care including asthma treatment, thereby demanding medications, devices and healthcare services, leading to growth in market reach.

Regional Analysis

A large patient pool deals with asthma in North America

In 2023, North America dominates the global asthma treatment market commanding an admirable market share of 51.2%. The regions’ inclination towards success is primarily by virtue of higher pervasiveness of asthma in North America in comparison to other geographies. The rise in asthmatic symptoms among population emphasizes the need for effective management strategies and accessibility to appropriate medical services.

The dominance is further attributed to existence of well-established pharmaceutical companies, robust research and development activities coupled with ameliorated healthcare infrastructure in the region, which further favors the expediting growth of the market in the region.

• In United states, approximately 26 million people or about 1 in 13 individuals are suffering from asthma.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

Manufacturers in the market are actively implementing various strategic initiatives to establish a robust position and enhance their overall presence. These initiatives encompass partnership & collaboration, acquisition & mergers, and increasing investments in research and development (R&D). By expanding their R&D capabilities, key players can effectively develop and launch innovative products, thereby expanding their product portfolio and securing a strong market position.

• To exemplify, AstraZeneca and Amgen’s Tezspire got US FDA approval for the add-on maintenance treatment of adults and pediatric patients for aged 12 or more dealing with severe asthma.

Top Key Players in the Asthma Treatment Market

• AstraZeneca
• Teva Pharmaceutical Industries
• Roche Holding AG/Novartis AG
• Sanofi-Aventis SA
• Mundi-Pharma
• GlaxoSmithKline Plc.
• Merck & Co, Inc.
• Regeneron
• Genentech Inc.
• Mylan N.V.
• Sumitomo Dainippon Pharma Co., Ltd.

Recent Developments

• In January 2023: A new drug combination was launched by Lupin (multinational pharmaceutical company) to manage and treat asthma among patients. The company launched the product under the brand name DIFIZMA in India comprising a fixed triple dose combination of Indacaterol, Glycopyrronium and Mometasone.
• In March 2022: Generic Drug Device Combination Product was approved by United States Food & Drug Administration to treat asthma and obstructive pulmonary disease in patients of 6 years old or older.
• In January 2022: A 40 mg pre-filled needle of Nucala formulated by GSK was approved by Food and Drug Administration (US). The medication is meant for kids aged 6-11 years dealing with extreme eosinophilic asthma.

Report Scope